Vanda Pharmaceuticals Inc.
GENETIC MARKERS FOR ENHANCING EFFICACY OF ANTIPSYCHOTIC TREATMENT WITH ILOPERIDONE
Last updated:
Abstract:
The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.
Status:
Application
Type:
Utility
Filling date:
29 Nov 2021
Issue date:
17 Mar 2022